MedTrace Logo

EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA

NCT02975752 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2016-11-29

No results posted yet for this study

Summary

First-line treatment with afatinib prolongs overall survival in patients with metastatic non-small-cell lung cancer (NSCLC) harboring EGFR exon 19 deletion mutations. Conversely, somatic KRAS mutations are negative predictors for benefit from EGFR-targeting agents. In this study we want to compare a new highly sensitive method for the detection of EGFRdelEx19 and KRAS Exon 2 with targeted-resequencing multiplex-PCR (NGS).

Conditions

  • Lung Adenocarcinoma Metastatic

Interventions

GENETIC

LC-RT-PCR and NGS

highly sensitive PCR vs. multiplex targeted-resequencing

Sponsors & Collaborators

  • University Hospital, Essen

    lead OTHER

Principal Investigators

  • Filiz Özkan, MD · Department of Interventional Pneumology

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-06-30
Completion
2016-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02975752 on ClinicalTrials.gov